<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002588</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2994</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-ICC-2994</secondary_id>
    <secondary_id>NCI-T94-0078D</secondary_id>
    <nct_id>NCT00002588</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia</brief_title>
  <official_title>Phase I Trial of Sequential Topotecan(NSC 609699)and Etoposide for Patients With Relapsed, Refractory,or High Risk Acute Myeloid or Lymphoid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of topotecan and etoposide in treating&#xD;
      patients who have recurrent or refractory leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of topotecan when combined with etoposide&#xD;
      in patients with relapsed or refractory acute myelogenous leukemia, acute lymphoblastic&#xD;
      leukemia, or blastic phase chronic myelogenous leukemia. II. Determine the toxicity of this&#xD;
      regimen in these patients. III. Measure serum levels of topotecan at steady state and&#xD;
      correlate them with any change in topoisomerase II content in leukemic blasts. IV. Assess&#xD;
      whether it is feasible to correlate any upregulation of topoisomerase II expression with&#xD;
      tumor response to etoposide in subsequent Phase II studies. V. Assess whether levels of&#xD;
      pretreatment expression of topoisomerases I and II in leukemic cells are predictive of&#xD;
      clinical response. VI. Assess whether it is feasible to develop a pharmacodynamic assay based&#xD;
      on posttreatment apoptotic changes in leukemic blasts and whether this could be correlated&#xD;
      with tumor response in subsequent phase II trials. VII. Determine the response in patients&#xD;
      treated with this regimen.&#xD;
&#xD;
      OUTLINE: Induction: 2-Drug Combination Chemotherapy. Topotecan, TOPO, NSC-609699; Etoposide,&#xD;
      VP-16, NSC-141540. Consolidation: 2-Drug Combination Chemotherapy. TOPO; VP-16.&#xD;
&#xD;
      PROJECTED ACCRUAL: 15-23 patients will be accrued in approximately 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1994</start_date>
  <completion_date type="Actual">January 2001</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of topotecan when combined with etoposide in patients with relapsed or refractory acute myelogenous leukemia, acute lymphoblastic leukemia, or blastic phase chronic myelogenous leukemia.</measure>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute myelogenous leukemia (M0-M7) and acute lymphoblastic&#xD;
        leukemia (L1-L2) Refractory or in first or subsequent relapse Circulating blasts present OR&#xD;
        Greater than 5% blasts in bone marrow Acute myelogenous leukemia secondary to&#xD;
        myelodysplastic syndrome or cytotoxic therapy Untreated OR Maximum of 2 intensive induction&#xD;
        regimens Chronic myelogenous leukemia in blastic or lymphoid crisis Untreated OR Maximum of&#xD;
        2 intensive induction regimens No CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-3 Life expectancy: At&#xD;
        least 4 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL AST&#xD;
        and ALT less than 3 times normal Alkaline phosphatase less than 3 times normal Renal:&#xD;
        Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min&#xD;
        Cardiovascular: No myocardial infarction within 6 months No active ischemic cardiac disease&#xD;
        No poorly controlled congestive heart failure No other symptomatic cardiac disease Left&#xD;
        ventricular ejection fraction at least 40% Pulmonary: No symptomatic restrictive or&#xD;
        obstructive lung disease Other: No severe neurologic disease No active infection unless&#xD;
        stable on antimicrobial therapy or fever is tumor related HIV negative Not pregnant or&#xD;
        nursing Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: At least 2 weeks since prior cytotoxic therapy (except&#xD;
        hydroxyurea and steroids) Biologic therapy: No prior bone marrow transplantation At least 3&#xD;
        days since prior hematopoietic growth factors Chemotherapy: No prior topotecan or&#xD;
        camptothecin analogues Prior etoposide allowed Endocrine therapy: Not specified&#xD;
        Radiotherapy: Not specified Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda W. Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cooper BW, Lazarus HM, Creger R, et al.: A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL) (Meeting abstact.). [Abstract] Proceedings of the American Society of Clinical Oncology 15: A1549, 1996.</citation>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brenda W. Cooper, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>L1 adult acute lymphoblastic leukemia</keyword>
  <keyword>L2 adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

